These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24636625)

  • 21. No money, no meds.
    Mabry M
    Newsweek; 1999 Jul; 134(2):32-3. PubMed ID: 10538648
    [No Abstract]   [Full Text] [Related]  

  • 22. The fragility of the U.S. vaccine supply.
    Sloan FA; Berman S; Rosenbaum S; Chalk RA; Giffin RB
    N Engl J Med; 2004 Dec; 351(23):2443-7. PubMed ID: 15575064
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug companies agree to cut price of HPV vaccine to developing countries to increase accessibility.
    Gulland A
    BMJ; 2013 May; 346():f3025. PubMed ID: 23667128
    [No Abstract]   [Full Text] [Related]  

  • 24. The Health Impact Fund: incentives for improving access to medicines.
    Banerjee A; Hollis A; Pogge T
    Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
    [No Abstract]   [Full Text] [Related]  

  • 25. Vaccine venture boosts health hopes.
    Butler D
    Nature; 2009 Sep; 461(7262):323. PubMed ID: 19759588
    [No Abstract]   [Full Text] [Related]  

  • 26. Licensing IP to ensure accessibility to vaccines and other immunisation-related products.
    Mehta JM
    Vaccine; 2001 Feb; 19(13-14):1581-7; discussion 1592-3. PubMed ID: 11166878
    [No Abstract]   [Full Text] [Related]  

  • 27. Apropos "New vaccines for developing countries: will it be feast or famine"?
    Arya SC; Agarwal N
    Am J Law Med; 2009; 35(4):691. PubMed ID: 20196288
    [No Abstract]   [Full Text] [Related]  

  • 28. Improving global health: the need to think 'outside the box'!
    Benatar SR
    Monash Bioeth Rev; 2003 Apr; 22(2):69-72. PubMed ID: 15069959
    [No Abstract]   [Full Text] [Related]  

  • 29. Pricing the advance market commitment.
    Stéphenne J
    Lancet; 2011 May; 377(9777):1572. PubMed ID: 21550482
    [No Abstract]   [Full Text] [Related]  

  • 30. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Win-win interactions between the public and private sectors.
    Batson A
    Nat Med; 1998 May; 4(5 Suppl):487-91. PubMed ID: 9585192
    [No Abstract]   [Full Text] [Related]  

  • 33. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
    Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544
    [No Abstract]   [Full Text] [Related]  

  • 34. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability.
    Knox RP; Kesselheim AS; Sarpatwari A
    JAMA; 2022 May; 327(17):1647-1648. PubMed ID: 35426909
    [No Abstract]   [Full Text] [Related]  

  • 36. Introducing new vaccines into developing countries: obstacles, opportunities and complexities.
    Clemens J; Jodar L
    Nat Med; 2005 Apr; 11(4 Suppl):S12-5. PubMed ID: 15812482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A work in progress.
    Bloice C; Hallinan C
    Revolution (Oakl); 2005; 6(6):14-21. PubMed ID: 16422557
    [No Abstract]   [Full Text] [Related]  

  • 38. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 39. Drive to vaccinate children in developing countries faces "acute crisis" because of high costs.
    Moszynski P
    BMJ; 2010 May; 340():c2576. PubMed ID: 20462931
    [No Abstract]   [Full Text] [Related]  

  • 40. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines.
    Tetteh E
    Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.